tradingkey.logo

Exagen falls after stock sale launch

ReutersMay 7, 2025 8:37 PM

Shares of diagnostic test maker Exagen XGN.O down 16.8% post-market to $5.68 on equity offering news

Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed

It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing

Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap

Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI